Padua Prediction Score for VTE Prophylaxis
The Padua Prediction Score is an 11-item risk assessment tool that identifies hospitalized medical patients at high risk for venous thromboembolism (VTE), with a score ≥4 indicating high risk and warranting pharmacologic thromboprophylaxis. 111
How the Padua Score Works
The Padua score assigns points to specific risk factors, with a maximum possible score of 20:
Risk Factors and Point Values
High-value items (3 points each):
- Reduced mobility
- Active cancer
- Previous VTE (excluding superficial thrombophlebitis)
- Known thrombophilic condition
Moderate-value item (2 points):
- Recent trauma and/or surgery (<1 month)
Low-value items (1 point each):
- Elderly age (>70 years)
- Heart and/or respiratory failure
- Acute myocardial infarction or ischemic stroke
- Ongoing hormonal treatment
- Obesity (BMI >30)
- Acute infection and/or rheumatologic disorder
Clinical Application Algorithm
Step 1: Calculate the Score
Add points for all applicable risk factors present at admission.
Step 2: Risk Stratification
- Low risk: Score 0-3 → VTE incidence without prophylaxis: 0.3%
- High risk: Score ≥4 → VTE incidence without prophylaxis: 11%
Step 3: Decision Making
For patients with Padua score ≥4: Initiate pharmacologic thromboprophylaxis unless contraindicated by bleeding risk. The data shows prophylaxis reduces VTE incidence from 11% to 2.2% (HR 0.13,95% CI 0.04-0.4), with major/clinically relevant bleeding occurring in only 1.6% of patients. 111
For patients with Padua score 0-3: Prophylaxis is generally not indicated, as the VTE risk (0.3%) does not justify the bleeding risk. 111
Important Considerations
Bleeding Risk Assessment
The Padua score addresses VTE risk only. You must also assess bleeding risk using the IMPROVE bleeding score (score ≥7 indicates high bleeding risk). In patients with both high VTE risk (Padua ≥4) and high bleeding risk (IMPROVE ≥7), clinical judgment is required to weigh the 11% VTE risk against the 4.1% major bleeding risk. 111
Choice of Prophylactic Agent
When prophylaxis is indicated, options include:
- Unfractionated heparin (UFH): ~$10/day, 2-3 times daily dosing
- Low-molecular-weight heparin (LMWH): ~$35/day, once daily dosing
- Fondaparinux: ~$60/day, once daily dosing
LMWH and UFH have similar efficacy and safety profiles, though LMWH may have slightly lower heparin-induced thrombocytopenia risk (1/1900 vs 7/1900, p=0.07). Choose based on ease of use, cost, and patient-specific factors. 2
Mechanical Prophylaxis
Do not use graduated compression stockings for VTE prophylaxis in medical patients—they are ineffective and cause skin damage. 2 Intermittent pneumatic compression may be considered only when pharmacologic prophylaxis is contraindicated, though evidence in medical patients is limited. 2
Common Pitfalls
Over-prescription in low-risk patients: Studies show 49-57% of patients with Padua score <4 inappropriately receive prophylaxis, exposing them to unnecessary bleeding risk. 34
Under-prescription in high-risk patients: Approximately 25% of patients with Padua score ≥4 do not receive indicated prophylaxis. 4
Lack of documentation: The score is only effective when actually calculated and documented. Simply having it available in order sets does not ensure appropriate use. 34
Ignoring bleeding risk: The Padua score alone is insufficient—concurrent bleeding risk assessment is mandatory. 111
Guideline Context
The 2018 American Society of Hematology guidelines endorse the Padua score as a validated tool for VTE risk stratification in medical inpatients. 111 However, the 2011 American College of Physicians guidelines emphasize that universal prophylaxis for all medical patients is not supported by evidence and that risk assessment should guide individualized decisions, not blanket performance measures. 2 This underscores that the Padua score is a decision-support tool, not a mandate for automatic prophylaxis in all patients.